Discounted Cash Flow
Mdxhealth S.A. Foreign
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2019 | $11.8m | $-43.7m | $-22.4m | -370.6% | $-0.69 |
| 2020 | $18.5m (56.6%) | $-28.7m (34.4%) | $-20.8m (7.1%) | -155.3% (58.1%) | $-0.34 (50.7%) |
| 2021 | $22.2m (20.5%) | $-29.0m (-1.2%) | $-23.4m (-12.8%) | -130.4% (16.0%) | $-0.24 (29.4%) |
| 2022 | $37.1m (66.6%) | $-44.0m (-51.9%) | $-36.9m (-57.4%) | -118.9% (8.9%) | $-0.28 (-16.7%) |
| 2023 | $70.2m (89.4%) | $-43.1m (2.1%) | $-24.2m (34.3%) | -61.4% (48.3%) | $-1.66 (-492.9%) |
| 2024 | $90.0m (28.3%) | $-37.7m (12.6%) | $-19.7m (18.7%) | -41.9% (31.8%) | $-1.16 (30.1%) |
| 2025 | $107.9m (19.8%) | $-35.4m (6.1%) | $-3.3m (83.0%) | -32.8% (21.6%) | $-0.67 (42.2%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.